Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
SBIR Fast Track Grant
"VDX-111: A Novel Targeted Therapeutic for Triple-Negative Breast Cancer"
Advanced Industry Accelerator Early Stage Capital Retention Grant